Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cancer care include heart checks? a pilot study puts two models to the test

NCT ID NCT07783607

Disease control Sponsor: University of Vermont Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This pilot study explores whether a structured heart-health assessment can be done successfully and on time for adults with multiple myeloma who are starting a new line of treatment. Participants will be assigned by chance to receive the assessment either from a clinician embedded in the oncology team or from their primary care provider. The study will measure how many people complete the assessment before treatment and within six months, as well as how well they follow medication and lifestyle recommendations. Because it is a small pilot, it is not designed to determine which approach leads to better health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cardiovascular risk assessment pathway (oncology-embedded or primary care-directed)
What this could lead to
If successful, this could establish a practical way to integrate heart-health checks into cancer care, potentially reducing heart complications in myeloma patients.
What could go wrong
This is a small pilot study, not designed to prove which approach is better. Results may not apply to all patients, and the assessments may not always be completed on time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 33 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2028

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of multiple myeloma. * Age 18 years or older. * Preparing to begin a new line of systemic multiple myeloma treatment in the newly diagnosed or relapsed or refractory setting. * Planned ongoing oncology care with anticipated clinical visits sufficient to coordinate study assessments at Months 3, 6, and 12. * For participants eligible for randomization, an established primary care provider who can be identified at enrollment and contacted by the study team if the participant is assigned to the primary care provider-directed pathway. * Ability to understand the study and willingness to provide written informed consent. Exclusion Criteria: * An acute cardiovascular condition requiring emergency evaluation or specialty cardiology management rather than routine cardiovascular risk assessment, as determined by the treating clinician. * Any condition that, in the investigator's judgment, would prevent meaningful participation in the study intervention or required assessments. * Hospitalization or an urgent need to begin multiple myeloma treatment is not an exclusion. Participants meeting the urgent-treatment criteria may enroll in the separate nonrandomized urgent-treatment cohort.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart disease risk factors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart disease risk factors Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Vermont Medical Center

    Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.